Charity backs R&D into Parkinson's drugs targeting mitochond...

The charity Parkinson’s UK has struck a £1 million partnership with NRG Therapeutics to develop drugs targeted at mitochondria that could protect cells producing dopamine, which have been d

Pfizer’s Revatio flunks paediatric hypertension study

ImmusanT abandons coeliac disease vaccine after phase 2 flop

FDA fast-tracks Lilly/Boehringer’s Jardiance for heart failu...

Oxford Biomedica signs ophthalmology R&D deal with Santen

UK biotech Oxford Biomedica and Japan’s Santen have begun an option and licence agreement to research and develop gene therapy products for an inherited retinal disease.

Spain's Sanifit raises €72 million for rare disease drug tri...

Sanifit has raised €72.2 million ($80.9m) in Spain’s largest private biotech fundraiser to finance phase 3 clinical development of its rare disease drug SNF472.